Skip to content
value.today

Qlaris Bio, Inc.

Total raised
$42 M
4 rounds on record
Latest round
$4 M
Jun 2026
First round on record
Aug 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Qlaris Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$4 MNo. 4$2 to $10 million

Qlaris Bio, Inc.: Raise no. 4, Jun 2026

Investors in this round

8 investors had bought by the notice of Jun 17, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Promissory Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara M. Wirostko · Executive Officer
  • Frederic Guerard · Executive Officer, Director
  • Adrienne Graves · Director
  • Andrew Danielson · Director
  • Robert M. Warner · Director
  • Ronald M. Hunt · Director
  • Wende M. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”

Signed by Frederic Guerard, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 17, 2026. Read the notice at the SEC.

debt, optionsSEC
Nov 2025$6 MNo. 3$2 to $10 million

Qlaris Bio, Inc.: Raise no. 3, Nov 2025

Investors in this round

8 investors had bought by the notice of Nov 17, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Promissory Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara M. Wirostko · Executive Officer
  • Thurein Htoo · Executive Officer, Director
  • Adrienne Graves · Director
  • Andrew Danielson · Director
  • Ronald M. Hunt · Director
  • Wende M. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”

Signed by Thurein Htoo, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 17, 2025. Read the notice at the SEC.

debt, optionsSEC
Apr 2024$24 MNo. 2$10 to $50 million

Qlaris Bio, Inc.: Raise no. 2, Apr 2024

Investors in this round

8 investors had bought by the notice of Apr 22, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara M. Wirostko · Executive Officer
  • Thurein Htoo · Executive Officer, Director
  • Adrienne Graves · Director
  • Andrew Danielson · Director
  • Ronald M. Hunt · Director
  • Wende M. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”

Signed by Thurein Htoo, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 22, 2024. Read the notice at the SEC.

equitySEC
Aug 2019$8 MNo. 1$2 to $10 million

Qlaris Bio, Inc.: Raise no. 1, Aug 2019

Investors in this round

6 investors had bought by the notice of Aug 28, 2019: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $27 M offered; $19 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara Wirostko · Executive Officer
  • Thurein Htoo · Executive Officer, Director
  • Andrew Danielsen · Director
  • Ron Hunt · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thurein Htoo, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Qlaris Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

That is all the official record says: Qlaris Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Qlaris Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Qlaris Bio, Inc.
NameRoleNamed in
Barbara M. WirostkoExecutive officerJun 2026
Frederic GuerardExecutive officerJun 2026
Thurein HtooExecutive officerNov 2025
Barbara WirostkoExecutive officerAug 2019
Adrienne GravesDirectorJun 2026
Andrew DanielsonDirectorJun 2026
Frederic GuerardDirectorJun 2026
Robert M. WarnerDirectorJun 2026
Ronald M. HuntDirectorJun 2026
Wende M. HuttonDirectorJun 2026
Thurein HtooDirectorNov 2025
Andrew DanielsenDirectorAug 2019
Ron HuntDirectorAug 2019
Wende HuttonDirectorAug 2019